CTLA4 and neoplasm: Lastly, a phase II randomized trial in recurrent or metastatic patients with PD-L1 low or negative tumors (< 25% expression on tumor cells) known as CONDOR failed to demonstrate enhanced efficacy of adding the CTLA-4 antibody tremelimumab to single agent durvalumab (ORR 7.8% vs. 9.2% for combination therapy and monotherapy, respectively) (87).